Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study Konvalesan Plazma COVID-19’da Endojen Antikor Yanıtını Azaltır: Retrospektif Kesitsel Bir Çalışma

Omma A., Erden A., Güven S. C., Ateş İ., KÜÇÜKŞAHİN O.

Turkish Journal of Hematology, cilt.38, sa.4, ss.321-324, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/tjh.galenos.2021.2021.0277
  • Dergi Adı: Turkish Journal of Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.321-324
  • Anahtar Kelimeler: COVID-19, Convalescent plasma, Antibody, Immunity
  • Gazi Üniversitesi Adresli: Hayır

Özet

© 2021, Turkish Society of Hematology. All rights reserved.Objective: The aim of this study is to investigate post-COVID-19 antibody titers in patients who received convalescent plasma (CP) in addition to standard-of-care treatment. Materials and Methods: Hospitalized COVID-19 patients who received CP in addition to standard care were retrospectively investigated. Patients who received CP with a recorded total COVID-19 antibody test result after treatment were included. From among hospitalized COVID-19 patients who received only standard care with a recorded total COVID-19 antibody test result, a control group matched for age, gender, and comorbidities was formed. Total COVID-19 antibody index levels were compared. Results: Thirty-three CP recipients were enrolled in the study. The control group consisted of 34 age-, gender-, and comorbidity-matched standard-care patients. Median total COVID-19 antibody index levels were significantly reduced in the CP group. Conclusion: Although CP therapy may have benefits for disease outcome, its potential ability to hamper long-term immunity may be a problem.